By Theo Marcell (editorial pen name) · Updated September 30, 2026 · We may have a financial affiliation with some entities featured on this page.
The short answer: Wegovy and Ozempic contain the same active ingredient, semaglutide, but they are separate FDA-approved products with separate labels. As of September 2026, Ozempic’s labeled uses center on type 2 diabetes, while Wegovy’s center on cardiovascular risk reduction, long-term weight reduction, and (injection only) MASH. Both come as weekly injections and daily tablets.
“If they’re both semaglutide, what’s the difference?” is one of the most common questions in this category. The short version is that a brand name follows a label, and a label follows the conditions a manufacturer asked FDA to approve the product for. This guide walks through those labels. It’s educational and isn’t medical advice. Which product, if any, fits a person is a question for a clinician who knows their history.
Are Wegovy and Ozempic the same drug?
They share an active ingredient, semaglutide, a GLP-1 receptor agonist. Per the prescribing information, it stimulates insulin release and lowers glucagon in a glucose-dependent way and slows stomach emptying. Novo Nordisk makes both brands.
What differs is the product: the indications, the dose strengths, the devices and tablets, and the instructions. Each brand has its own prescribing information, and the sections that matter most (what it’s indicated for, how the dose is raised, what to do about a missed dose) are written separately. “Same molecule” doesn’t mean “same product.”
What is each brand approved for?
The table below is a high-level map, checked against current prescribing information on DailyMed as of September 2026. It covers both the injection and oral form of each brand. Labels change, so confirm details against the current label for the exact product.
| Brand (form) | Labeled uses as of September 2026 (high level) | Notes from the label |
|---|---|---|
| Ozempic (weekly injection) | Adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes; reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. | Not a weight-management label. Label revised 5/2026. |
| Ozempic (daily tablet) | Adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes; reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them. | Shares a label with Rybelsus tablets. Label revised 1/2026. The two tablet products aren’t substitutable milligram for milligram. |
| Wegovy (weekly injection) | With a reduced-calorie diet and more physical activity: reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; reducing excess body weight and maintaining the reduction long term in adults and children 12 and older with obesity, and in adults with overweight plus at least one weight-related condition; treating noncirrhotic MASH with moderate to advanced liver fibrosis in adults. | The MASH indication is under accelerated approval and may depend on a confirmatory trial. Label revised 6/2026. |
| Wegovy (daily tablet) | With a reduced-calorie diet and more physical activity: reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; reducing excess body weight and maintaining the reduction long term in adults with obesity, or with overweight plus at least one weight-related condition. | Adults only. No MASH or pediatric indication on the tablet listing. Same combined Wegovy label as the injection. |
Two patterns stand out. Ozempic’s labels are built around type 2 diabetes and the cardiovascular and kidney outcomes that go with it. Wegovy’s are built around obesity or overweight, plus cardiovascular risk reduction and liver disease. The Wegovy label also says that using it with other semaglutide-containing products or other GLP-1 receptor agonists isn’t recommended.
Does the evidence behind each label differ?
Yes, because the labels were earned in different populations. A few examples from the Ozempic prescribing information, in absolute terms:
- SUSTAIN 6: 3,297 adults with type 2 diabetes and cardiovascular disease, minimum observation time of 2 years. A major cardiovascular event occurred in 6.6% on Ozempic and 8.9% on placebo.
- FLOW: 3,533 adults with type 2 diabetes and chronic kidney disease, median follow-up 41 months. The kidney and cardiovascular composite occurred in 18.7% on Ozempic and 23.2% on placebo.
These are trial results in specific populations, not predictions for any one person. For the trials behind Wegovy’s weight and cardiovascular labels, our plain-English guide to the STEP, SURMOUNT, and SELECT trials explains what each one studied.
How do the labels describe dosing?
This section is about reading the label, not choosing a dose.
- Frequency: The injections are once-weekly. The tablets are once-daily and come with their own rules: per the labels, they’re taken on an empty stomach with a small amount of plain water, followed by a wait before food, drink, or other oral medicines.
- Gradual increases: Each prescribing information describes starting low and increasing in stages, and says the step-up is meant to reduce the risk of gastrointestinal side effects. Your clinician determines the dose, including whether and when it changes.
- Different strengths, different ladders: Ozempic and Wegovy use their own strengths and maintenance ranges, and Ozempic tablets and Rybelsus tablets are explicitly not interchangeable milligram for milligram. Don’t assume a number from one brand applies to another.
- Missed doses: The rules differ by product and form. The Medication Guide and Instructions for Use for your exact product are the reference, and a pharmacist can walk you through them.
- Switching forms: The Wegovy label has a section on moving between its injection and tablets. That’s a prescriber’s decision, not a DIY conversion.
How do the risks and warnings compare?
Closely. The Ozempic and Wegovy labels carry a boxed warning about thyroid C-cell tumors seen in rodents, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both list warnings for acute pancreatitis, gallbladder disease, kidney injury linked to dehydration, severe gastrointestinal reactions, serious allergic reactions, and pulmonary aspiration during anesthesia or deep sedation, so tell your care team about any planned procedure.
Some warnings follow the population. Ozempic’s label highlights low blood sugar with insulin or sulfonylureas and diabetic retinopathy complications. The Wegovy label also addresses blood sugar monitoring in people with diabetes. Nausea, vomiting, diarrhea, abdominal pain, and constipation are the most common side effects listed on the Ozempic label. For the full list, read the current Medication Guide.
What tends to shape the choice?
These are themes people often raise with their clinicians. They aren’t recommendations.
- Diagnosis and labeled use: Is the goal tied to type 2 diabetes, kidney disease, weight, cardiovascular risk, or liver disease?
- Format: Does a weekly injection or a daily tablet with food and water timing rules fit better?
- Safety history: Pancreas, gallbladder, stomach, thyroid, eye, and kidney history all matter, as do pregnancy plans.
- Practical factors: Coverage, out-of-pocket cost, and supply often matter as much as pharmacology.
If you’re comparing semaglutide with tirzepatide, start with our semaglutide vs tirzepatide comparison. The tirzepatide brand pair is covered in Zepbound vs Mounjaro.
Why does coverage differ between the two?
Insurers often consider the labeled indication along with their own plan rules, so a product labeled for type 2 diabetes and one labeled for weight reduction may be treated differently. Coverage, prior authorization, and cash prices vary by plan, employer, and state, and they change often. We don’t track prices here. Current coverage and cost details are best checked with your plan and pharmacy.
What recent label changes are worth knowing?
Label news moves quickly. These are dated one-liners drawn from the labels themselves.
- Jan 2026: The shared Rybelsus and Ozempic tablets label was revised to 1/2026 on DailyMed.
- May 2026: The Ozempic injection label was revised to 5/2026.
- June 2026: The Wegovy label was revised to 6/2026; DailyMed lists a new “Never Share WEGOVY FlexTouch Between Patients” warning (5.11).
Key takeaways
- Wegovy and Ozempic both contain semaglutide but have separate labels, strengths, and instructions.
- As of September 2026, Ozempic is labeled for type 2 diabetes, with cardiovascular and kidney indications in that population. Wegovy is labeled for weight reduction, cardiovascular risk reduction, and (injection) MASH.
- Each brand comes in an injection and a tablet form, with different rules for each.
- Labels describe gradual dose increases. Your clinician determines the dose.
- Coverage and cost details change often; check current plan information.
FAQ
Is Wegovy just a higher dose of Ozempic? Not exactly. They’re separate products with separate labels, indications, and dosing instructions. Dose strength is only one of the differences, and the labels aren’t interchangeable.
Can you take Wegovy and Ozempic together? The Wegovy label says using it with other semaglutide-containing products or any other GLP-1 receptor agonist isn’t recommended. Any decision about this belongs to your prescribing clinician.
Is Ozempic approved for weight loss? No. As of September 2026, the Ozempic labels cover type 2 diabetes and related cardiovascular and kidney risk reduction, not weight management. Wegovy carries the weight-reduction indication.
Do both brands come as pills? Yes. As of September 2026, each brand has a daily tablet listed on DailyMed (Ozempic tablets share a label with Rybelsus; Wegovy tablets share a label with Wegovy injection). Tablets have their own administration rules, and the shared Rybelsus and Ozempic tablet label says those two tablet products aren’t substitutable milligram for milligram.
Are these medicines safe for everyone? No. Both carry a boxed warning about thyroid C-cell tumors seen in rodents, and other warnings are listed in each prescribing information.
This article is for general education and isn’t medical advice. Talk with a licensed clinician before starting, stopping, or changing any medication.
We may have a financial affiliation with some entities featured on this page.
References
- Ozempic injection prescribing information (DailyMed, revised 5/2026): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- Rybelsus and Ozempic tablets prescribing information (DailyMed, revised 1/2026): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
- Wegovy injection and tablets prescribing information (DailyMed, revised 6/2026): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b